There is a saying in laboratory medicine that is not actually a saying, but should be: the test only tells you what you measured, not what you should have measured instead. Nowhere is this more relevant than in testosterone replacement therapy monitoring, where the gap between what gets checked and what should get checked is responsible for a meaningful fraction of suboptimal outcomes.
TRT is a hormone therapy that requires sustained laboratory oversight. This is not an administrative formality — it is the mechanism by which dose adequacy, safety thresholds, and clinical response are confirmed. The labs are not a bureaucratic inconvenience attached to the therapy. They are an integral part of how the therapy works.
Understanding which tests matter, why they matter, and what the results actually mean is useful both for patients trying to navigate their own care and for clinicians trying to explain it. This post provides that framework.
The Baseline Battery
Before initiating TRT, a baseline panel establishes the starting point against which subsequent values will be compared. The standard components:
Total testosterone: The primary diagnostic marker. Drawn fasting in the early morning — typically before 10 AM — to capture peak diurnal levels. Most guidelines require two separate morning measurements below the relevant threshold before diagnosis is confirmed, because testosterone levels vary day to day by 10 to 15% or more. A single low reading on a Tuesday afternoon is not a diagnosis.
LH and FSH: These gonadotropins distinguish primary from secondary hypogonadism. High LH/FSH with low testosterone indicates the testes are receiving the signal but failing to respond (primary hypogonadism, testicular failure). Low or inappropriately normal LH/FSH with low testosterone indicates the signal is absent or weak (secondary hypogonadism, hypothalamic-pituitary dysfunction). The distinction guides workup: a secondary pattern warrants evaluation for pituitary pathology, including prolactinoma, before TRT is initiated.
SHBG (sex hormone-binding globulin): SHBG binds testosterone tightly, rendering it biologically unavailable. Up to 20% of men with total testosterone above 300 ng/dL have low bioavailable testosterone when SHBG is elevated — conditions like obesity, insulin resistance, and hypothyroidism tend to lower SHBG, while aging, liver disease, and certain medications tend to raise it. The BSSM recommends free testosterone assessment in borderline cases for exactly this reason.
Hematocrit (or hemoglobin/complete blood count): Testosterone stimulates erythropoiesis, meaning it increases red blood cell production. This is the most important safety parameter in TRT monitoring. The baseline establishes where the patient starts; subsequent monitoring confirms whether the therapy is pushing hematocrit to concerning levels.
PSA (prostate-specific antigen): The prostate concern that dogged testosterone therapy for decades has been substantially revised, but PSA monitoring remains standard practice. Baseline PSA establishes the starting value against which future changes are assessed; it also identifies men with unrecognized prostate pathology before therapy begins.
Estradiol: Testosterone aromatizes to estradiol, and this conversion varies between individuals. High estradiol can cause gynecomastia, water retention, and mood changes in men on TRT. It also mediates many of testosterone’s benefits in bone. Knowing the baseline — and subsequent levels — allows for management when conversion is excessive.
Lipids and metabolic markers: Testosterone affects lipid metabolism; some formulations and doses can suppress HDL. A baseline lipid panel is standard, with monitoring if significant changes are expected.
The Monitoring Schedule
The cadence of monitoring is not arbitrary. It follows the pharmacokinetic logic of the therapy: check at the point when the drug’s effects are most likely to have manifested, and adjust from there.
For transdermal preparations (including the Hypospray spray platform), the Endocrine Society guidelines recommend checking testosterone levels at 3 to 14 days after the initial application, drawing blood mid-morning on a day when the patient has applied the product earlier that morning. This is the steady-state window for daily transdermal products.
The standard monitoring schedule after initiation:
3 months: Total testosterone, hematocrit (or complete blood count), PSA. This is the first meaningful safety checkpoint. The hematocrit concern primarily manifests in the first few months of therapy.
6 months: Repeat the core panel. Dose adjustment, if needed, is based on the combination of measured levels and symptom response. Sexual symptoms typically improve within 6 weeks of starting therapy; other benefits — bone density, metabolic markers, mood — may take 12 months or longer to become apparent.
12 months: Full panel including testosterone, hematocrit, PSA, estradiol, SHBG, and metabolic markers. By this point, the therapy’s effects on the patient’s particular physiology are clearly visible.
Annually thereafter: The full panel repeated on a stable yearly cycle.
Keen Meds’ 6-month check-in cycle — blood kit, laboratory analysis, telehealth consultation, and refill authorization — maps directly onto this clinical logic. The check-in is not an administrative process. It is the monitoring component of a medically supervised therapy.
The Hematocrit Threshold: Where Things Get Serious
Elevated hematocrit — polycythemia — is the most common clinically significant adverse effect of testosterone therapy. It occurs because testosterone stimulates erythropoietin secretion and directly affects erythroid progenitor cells in the bone marrow. IM injections, because of their supratherapeutic peaks, are associated with higher rates of polycythemia than transdermal preparations. Daily transdermal delivery, with its flatter pharmacokinetic profile, reduces but does not eliminate the risk.
The threshold question is where the guidelines diverge. American guidelines contraindicate testosterone when hematocrit exceeds 50%. European guidelines use 54% as the upper limit. This difference reflects different assessments of where the thromboembolic risk becomes unacceptable — elevated hematocrit increases blood viscosity, which increases the risk of clot formation and events like deep vein thrombosis, pulmonary embolism, and stroke.
When hematocrit exceeds 54%, management options include dose reduction, switching delivery route, extended dosing intervals, or therapeutic phlebotomy. After levels fall below 50% and secondary causes of erythrocytosis are excluded, therapy can resume at a reduced dose. This is a manageable complication when monitored appropriately. It is not manageable when it goes undetected.
The PSA Picture in 2025
The prostate cancer concern that was a major barrier to TRT prescribing for decades has been substantially reframed. The saturation model — proposed initially by Abraham Morgentaler — holds that prostate androgen receptors are essentially saturated at relatively low testosterone concentrations, meaning that raising testosterone from hypogonadal to normal levels does not meaningfully increase prostate stimulation. Multiple lines of evidence now support this model.
The Xu et al. 2024 meta-analysis of 28 randomized controlled trials in the journal Frontiers in Endocrinology found that PSA levels did not differ significantly between TRT and placebo groups (weighted mean difference 0.08 ng/mL; 95% CI -0.00 to 0.17; P=0.06). Prostate volume similarly showed no significant difference. TRT does not appear to drive prostate growth or PSA elevation in men with hypogonadism when given at physiological replacement doses.
PSA monitoring nonetheless remains standard and appropriate — not because TRT causes prostate cancer, but because prostate cancer exists independently in the population being treated, and TRT can unmask it by bringing testosterone to normal levels. The monitoring is a surveillance function, not a drug toxicity function.
Current guidelines recommend referral to a urologist if PSA rises more than 1.4 ng/mL within 12 months, or if absolute PSA exceeds 4.0 ng/mL. The 95th percentile for PSA increase at 3 months is 1.2 ng/mL; at 12 months, 1.7 ng/mL — these reference values frame what “normal variation” looks like during TRT.
What the Numbers Actually Tell You
The labs answer specific questions:
- Is the dose working? (Total testosterone, free testosterone, symptoms)
- Is the dose safe? (Hematocrit, PSA, lipids)
- Is conversion appropriate? (Estradiol)
- Is the diagnosis right? (LH/FSH, if second-line evaluation is needed)
They do not answer: Is the patient’s quality of life improved? Is this the right therapy for this person’s particular situation? Is there a better delivery method for this patient’s household risk factors?
Those questions require a clinical conversation. The labs provide the evidence base for that conversation. They are the scoreboard, not the game.
Next up: Post 3 examines one of the most clinically contested questions in testosterone medicine: the functional hypogonadism patient — the man whose testosterone is low because he is obese, sleep-deprived, or metabolically ill rather than because his HPT axis has failed. Does he need testosterone, lifestyle intervention, or both? Post 3: The Functional Hypogonadism Question.
